tirzepatide average weight loss first month What to Expect on Tirzepatide: Month-by-Month Timeline First Month Weight Loss on

Consistent with previous research, SES also emerged as a key variable, with individuals in medium-SES regions showing an elevated risk than those in high-SES areas

GLP-1 receptors (which respond to the GLP-1 we produce) are found in the pancreas, the gut, and in the brain, including in regions involved in dopamine signaling and addiction

Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously

Most GLP1 side effects are GI-related (nausea, constipation) and improve as your body adjusts